Publications (18) Publications de María José García Barchino

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  2. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545

  2. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

  3. Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in b lymphoid neoplasms

    Haematologica, Vol. 103, Núm. 6, pp. 1065-1072

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

2016

  1. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

    Oncotarget, Vol. 7, Núm. 25, pp. 37407-37419

2014

  1. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

    Blood, Vol. 123, Núm. 26, pp. 4111-4119

2011

  1. LIF, a novel STAT5-regulated gene, is aberrantly expressed in myeloproliferative neoplasms

    Genes and Cancer, Vol. 2, Núm. 5, pp. 593-596

  2. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer

    Breast Cancer Research, Vol. 13, Núm. 1

2009

  1. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes

    Journal of Endocrinology, Vol. 203, Núm. 1, pp. 99-110

2002

  1. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer

    Clinical Cancer Research, Vol. 8, Núm. 12, pp. 3863-3869

  2. NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer

    Clinical Cancer Research, Vol. 8, Núm. 2, pp. 347-353

2001

  1. Protection by nitric oxide against liver inflammatory injury in animals carrying a nitric oxide synthase-2 transgene.

    The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 15, Núm. 3, pp. 583-585

2000

  1. Age-related changes of liver antioxidant enzymes and 8-hydroxy-2'-deoxyguanosine during fetal-neonate transition and early rat development

    IUBMB Life, Vol. 49, Núm. 6, pp. 497-500